Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9410
Title: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.
Authors: Cao, Zemin;Bonnet, Fabrice;Candido, Riccardo;Nesteroff, Stefan P;Burns, Wendy C;Kawachi, Hiroshi;Shimizu, Fujio;Carey, Robert M;De Gasparo, Marc;Cooper, Mark E
Affiliation: Department of Medicine, Austin & Repatriation Medical Centre (Repatriation Campus), University of Melbourne, Heidelberg West, Victoria 3081, Australia. cao@austin.unimelb.edu.au
Issue Date: 1-Jul-2002
Citation: Journal of the American Society of Nephrology : Jasn; 13(7): 1773-87
Abstract: The role of the angiotensin type 2 (AT(2)) receptor in the pathogenesis of progressive renal injury has not been previously elucidated. The renal expression of the AT(1) and AT(2) receptors in subtotally nephrectomized rats (STNx) and the effects of AT(2) receptor blockade on renal injury were explored. Reduced renal expression of the AT(1) but not the AT(2) receptor was observed in STNx by reverse transcription-PCR, by in vitro autoradiography, and by immunohistochemical staining. The STNx rats were randomly assigned to AT(1) receptor antagonist valsartan, AT(2) receptor antagonist PD123319, or the combination of both for 4 wk. Increased proteinuria in STNx rats was reduced by PD123319 but to a lesser degree when compared with valsartan. Reduced gene and protein expression of the slit diaphragm protein nephrin was prevented by either valsartan or PD123319. Expression of osteopontin, proliferating cell nuclear antigen, and monocyte/macrophage infiltration was increased in STNx rats and was reduced by both AT(1) and AT(2) receptor antagonists. These effects of AT(2) receptor antagonism were observed in the presence of increased BP in STNx rats. These findings suggest that blockade of the AT(2) receptor alone confers a degree of renal protection; in particular, it seems that the combination of the AT(1) and AT(2) receptor antagonists may confer additive renal effects than either receptor antagonist as monotherapy.
Internal ID Number: 12089373
URI: http://ahro.austin.org.au/austinjspui/handle/1/9410
URL: http://www.ncbi.nlm.nih.gov/pubmed/12089373
Type: Journal Article
Subjects: Angiotensin Receptor Antagonists
Animals
Blood Pressure.drug effects
Body Weight.drug effects
Cytoprotection
Diuresis.drug effects
Gene Expression
Imidazoles.pharmacology
Kidney.drug effects.metabolism.pathology
Kidney Diseases.genetics.metabolism.pathology.physiopathology
Male
Membrane Proteins
Nephrectomy.methods
Organ Size.drug effects
Proteins.genetics.metabolism
Pyridines.pharmacology
Rats
Rats, Sprague-Dawley
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin.metabolism
Tetrazoles.pharmacology
Valine.analogs & derivatives.pharmacology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.